Related Experiment Video
Updated: Dec 23, 2025
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
Biomarkers for Immunotherapy
Jean G Bustamante-Alvarez1, Dwight H Owen1
1Division of Medical Oncology, Department of Internal Medicine, Ohio State University Wexner Medical Center, 320 West 10th Avenue, A450B Starling Loving Hall, Columbus, OH 43210, USA.
Abstract:
Immune checkpoint inhibitor (ICI) therapy has been approved for several solid tumors, including non-small cell lung cancer. ICIs have shown unprecedented durable responses and higher response rates than chemotherapy in selected patients. The development of biomarkers that serve as predictors of response is crucial for treatment selection. Evidence suggests that the response to immunotherapy depends on tumor genomics and the interactions with the immune system and the tumor microenvironment. This article reviews the data supporting the use of these biomarkers to optimize patient selection for these therapies and explores biomarkers that are the focus of ongoing research.
Insights
Biomarkers are crucial for predicting patient response to immune checkpoint inhibitor (ICI) therapy in solid tumors like non-small cell lung cancer. Understanding tumor genomics and the tumor microenvironment aids in selecting patients for immunotherapy.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Immune checkpoint inhibitors (ICIs) offer durable responses in several solid tumors, including non-small cell lung cancer, outperforming chemotherapy in select patients.
- Predictive biomarkers are essential for optimizing patient selection and treatment strategies for ICI therapy.
- Tumor genomics and the tumor microenvironment significantly influence response to immunotherapy.
Purpose of the Study:
- To review existing data on biomarkers for predicting response to immune checkpoint inhibitor therapy.
- To explore novel biomarkers currently under investigation for optimizing patient selection.
- To enhance the efficacy of immunotherapy by improving patient stratification.
Main Methods:
- Literature review of studies investigating biomarkers for immune checkpoint inhibitor response.
- Analysis of data linking tumor genomics, immune system interactions, and tumor microenvironment to treatment outcomes.
- Synthesis of evidence supporting the use of established and emerging biomarkers.
Main Results:
- Biomarkers related to tumor genomics and the immune microenvironment show promise in predicting ICI response.
- Established biomarkers aid in selecting patients who are likely to benefit from immunotherapy.
- Ongoing research is identifying new biomarkers for broader application.
Conclusions:
- Biomarker-driven patient selection is critical for maximizing the benefits of immune checkpoint inhibitors.
- Further research into tumor genomics and the tumor microenvironment will refine predictive models.
- Optimizing patient selection through biomarkers will improve outcomes in non-small cell lung cancer and other solid tumors.
